Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based drugmaker Pfizer has ended its plan to market an over-the-counter (OTC) version of its cholesterol pill Lipitor in the US market.
Subscribe to our email newsletter
In December 2014, the company completed a Phase III actual use trial, which was intended to simulate the OTC use of Lipitor (atorvastatin calcium) 10mg.
The program was terminated as the trial did not meet its primary objectives of showing patient compliance with the direction to check their low-density lipoprotein cholesterol (LDL-C) level and, after checking their LDL-C level, took appropriate action based on their test results.
Pfizer said in a statement: "Based on dialogue with the FDA about the program and analysis of this data, the program was terminated."
Initiated in October 2013, the Phase III actual use trial enrolled around 1,311 patients.